The global Postmenopausal Osteoporosis Market is estimated to be valued at US$ 4,747.9 Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Postmenopausal osteoporosis is a condition where bones become brittle and fragile from loss of tissue, typically in the spine, hips and wrists. Drugs associated with postmenopausal osteoporosis help increase bone mineral density and reduce the risk of fractures.
Market key trends:
One of the key trends fueling the growth of this market is the ongoing research into drug combinations for postmenopausal osteoporosis treatment. Several pharmaceutical companies are conducting clinical trials to test the safety and efficacy of combining different drug classes like bisphosphonates with parathyroid hormone analogs to develop more effective treatment regimens. If proven successful, such drug combinations could receive regulatory approvals and change the standard of care, driving significant growth in the market.
Segment Analysis
The global postmenopausal osteoporosis market is segmented into type and route of administration. Based on type, the market is bifurcated into bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, parathyroid hormone therapy, and others. The bisphosphonates segment currently dominates the market due to high efficacy, low risk of side effects, and extensive usage of bisphosphonate drugs such as alendronate and risedronate for osteoporosis treatment.
Based on route of administration, the market is segmented into oral and parenteral. The oral segment accounts for the largest share due to ease of administration.
Key Takeaways
The Global Postmenopausal Osteoporosis Market Size was valued at US$ 4,747.9 million in 2023 and is expected to witness high growth, exhibiting CAGR of 4.4% over the forecast period due to increasing geriatric population and the subsequent rise in osteoporosis cases.
Regional analysis:
North America accounted for the largest share of the global market in 2023 due to high awareness about osteoporosis and well-developed healthcare infrastructure in the region. Asia Pacific is expected to grow at the highest CAGR during the forecast period. This can be attributed to rising cases of osteoporosis due to changing lifestyles in countries like China and India.
Key players analysis:
Key players operating in the postmenopausal osteoporosis market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc. Enzene Biosciences, Samsung BioepisL Radius Health, Inc., Alvotech, and AryoGen Pharmed.
For More Insights, Read: https://www.newsstatix.com/postmenopausal-osteoporosis-market-size-share-and-growth-forecast-2023-2030/
Comments
0 comment